key: cord-0759882-iss1iq12 authors: Campos, Daniel Melo de Oliveira; Fulco, Umberto Laino; de Oliveira, Claudio Bruno Silva; Oliveira, Jonas Ivan Nobre title: SARS‐CoV‐2 virus infection: Targets and antiviral pharmacological strategies date: 2020-10-14 journal: J Evid Based Med DOI: 10.1111/jebm.12414 sha: 70d82ef95c4e997ff1b7b09863a9a14f8974253f doc_id: 759882 cord_uid: iss1iq12 The current pandemic of coronavirus disease 2019 (COVID‐19), transmitted person‐to‐person by severe acute respiratory syndrome of coronavirus 2 (SARS‐CoV‐2), poses a threat to global public health. To present, these are still no clinically approved antibodies or drugs specific for SARS‐CoV‐2, which makes it difficult for controlling the associated pandemic, limited to monitoring and containment. This situation generates a new need for the development of safe and effective treatments. Since SARS‐CoV‐2 shares phylogenetic traits with SARS‐CoV and MERS‐CoV, antiviral medicines may provide some insight into the development of COVID‐19 therapeutics. Besides that, they are being prioritized several FDA‐approved drugs due to the pandemic state. Despite recent advances in the control of the current COVID‐19 pandemic, challenges such as the rapid virus spread and the socioeconomic cost of this outbreak remain for the inexistence of therapeutics agents against SARS‐CoV‐2. From this moment, the in vivo evaluation of FDA‐approved drugs, which until then appears to be effective are recommended, such as chloroquine, hydroxychloroquine, remdesivir, favipiravir, nitazoxanide, and ivermectin; besides new targets: Mpro, spike glycoprotein, and TMPRSS2 inhibitors. Therefore, these investigations are needed to prove the efficacy and safety of these potential candidates, including their side effects. transport of nutrients across cell membranes; the E protein plays a role in the assembly and release of the virus, and is involved in viral pathogenesis; and the N protein can bind to the viral RNA genome and maintain its stability. 6, 7 The current pharmacological strategies against COVID-19 are based on improve the immune responses to SARS-CoV-2 and prevent its severe complications. 6 To date, there are no clinically approved antibodies or drugs specific for SARS-CoV-2, making the control of the associated pandemic difficult; therefore, health services are limited to monitoring and containment of the virus. This situation requires the development of safe and effective treatments, and investigation into the history of treatments for similar outbreaks is necessary to extrapolate potential antiviral therapies. [1] [2] [3] SARS-CoV-2 shares phylogenetic traits with SARS-CoV and MERS-CoV; therefore, antiviral treatments effective against these viruses may provide some insight into the development of therapeutics for COVID-19. Due to the nature of the pandemic, priority is being given to FDA-approved drugs or clinical trial candidates in Phase III that are close to being commercialized. [1] [2] [3] Also, the immunotherapies may be effective in the early stages of infection. The use of convalescent plasma, intravenous immunoglobulin, and monoclonal antibodies can provide virus-neutralizing and inhibition effects. The lung damage of COVID-19 is, at least partially, mediated by the immune response against the virus, and it is theoretically possible that modulating that inflammation by TNF-α, IL-17, and IL-23 inhibition might even be protective. 4, 8 The molecular interaction of the virus with the host cell represents a promising therapeutic target for identifying SARS-CoV-2 antiviral drugs and is the main target of neutralizing antibodies (Abs) upon infection. The coronavirus enters the host cell via binding of S glycoprotein on the viral surface to angiotensin-converting enzyme 2 (ACE2) on the cell surface, which is triggered by transmembrane serine protease 2 (TMPRSS2). The S2 subunit of S glycoprotein is responsible for mediating virus fusion and entry into the host cell, where heptad repeat 1 (HR1) and 2 (HR2) bring viral and cellular membranes in proximity for fusion. 6, 9 The binding affinity of the S protein-ACE2 complex of SARS-CoV-2 is approximately 10-20 times higher than that of SARS-CoV. A high-throughput in silico screening approach used to investigate FDA-approved compounds in the LOPAC library identified KT185, KT203, GSK1838705A, BMS195614, and RS504393 (Eptifibatide acetate, TNP, GNF5, GR 127935 hydrochloride hydrate, and RS504393, respectively). These compounds were shown to interact with the receptor-binding site on the viral S protein (similar to the virus binding motifs of ACE2), and are therefore potential drugs for the inhibition of viral infection. 10 The lectin griffithsin is one of the most potent broad-spectrum antivirals, and viral entry inhibitors discovered to date. 11 This binds to the oligosaccharides of various viral surface glycoproteins, including those found on HIV, MERS, SARS, HCV, and HSV. 12 Griffithsin has been tested for HIV prevention in Phase I stud- ies, but the potency and delivery systems of known S protein inhibitors should be reevaluated for the treatment or prevention of COVID-19. TMPRSS2 is a host protein that sits on the cell membrane and is considered a promising drug target. This serine protease is critical to the entry of coronaviruses into host cells by cleaving and activating the viral S protein, and viral entry has been blocked by a clinically proven inhibitor of TMPRSS2, imatinib. 1, 13, 14 From this perspective, it is believed that other serine protease inhibitors such as imatinib, camostat, and nafamostat can efficiently block SARS-CoV, MERS-CoV, and SARS-CoV-2 cell entry, which could be a promising treatment for COVID-19 infection. 14-16 The main protease (Mpro, also known as 3C-Like protease) of SARS-CoV-2 functions in the processing of polyproteins and virus maturation, cleaving nsp4-nsp16. The crucial role of Mpro in viral replication and its high sequence conservation with SARS-COV Mpro (96% homology) makes this enzyme a promising antiviral target. 1, 17, 18 Studies have adopted a computational approach to screen for available medicines which may function as inhibitors of SARS-CoV-2 Mpro. Based on the chemical structures of the potential drugs and conformational changes in the active site, binding of SARS-CoV-2 Mpro occurs with the following compounds: colistin, valrubicin, icatibant, bepotastine, epirubicin, epoprostenol, vapreotide, aprepitant, caspofungin, and perphenazine. 19 In addition, similar studies have highlighted the compounds myristicin, methyl rosmarinate, calceolarioside B, licoleafol, amaranthine, nelfinavir, and prulifloxacin from a total of 32 297 potential antiviral phytochemicals, 20 and nelfinavir in combination with the inhibitor N3 showed potential for inhibition during in vitro studies. 1, 17, 21 A previous attempt to predict drugs that inhibited SARS-CoV Mpro identified two HIV-1 protease inhibitors, lopinavir and ritonavir (LPV/r), as potential candidates, both of which bind to the same target site of Mpro. 22 These drugs were assessed for activity against SARS-CoV-2 using in silico studies, and administration of LPV/r to infected COVID-19 patients appeared to show therapeutic effect, lowering the body temperature and restoring standard physiological mechanisms with no apparent toxicity or side effects. 23 However, LPV/r treatment did not result in benefits beyond standard therapy in severe cases of COVID-19, while a retrospective study found no protective effect of these drugs for the treatment of nonsevere COVID-19 patients. 24, 25 In order to fully investigate the efficacy of LPV/r antiviral treatment, a Phase IV randomized controlled trial of LPV/r for COVID-19 treatment is being carried out (No.NCT04255017). Attention has shifted to remdesivir and favipiravir, drugs with a wide spectrum of action which possibly have the highest potential for the effective treatment of COVID-19. These drugs are nucleoside analogs that act as RNA-dependent RNA polymerase (RdRp) inhibitors, capable of interfering with the action of viral RNA replicase and avoiding proofreading by viral exoribonuclease (ExoN), inhibiting the replication of multiple coronaviruses in respiratory epithelial cells. 25, 26 Remdesivir is highly effective and safe in controlling COVID-19 infection. In SARS-CoV-2 infected Vero E6 and Huh-7 cells, remdesivir and favipiravir showed inhibition at micromolar concentrations. 26 A report was recently published describing the successful administra- it is challenging to put remdesivir into large-scale clinical use. 28, 29 Although favipiravir showed a higher inhibitory concentration than remdesivir against SARS-CoV-2, favipiravir was shown to have 100% efficacy against the Ebola virus, which has a similar inhibitory concentration. 26 A study comparing favipiravir and LPV/r for the treatment of patients infected with COVID-19 reported that favipiravir resulted in a better therapeutic response in terms of disease progression and viral clearance. 30 In addition, favipiravir can inhibit the binding of the viral envelope and ORF7a proteins to porphyrin, preventing the virus from entering host cells and freeing porphyrins. 31 The antimalarial chloroquine (CQ), along with its analogue hydrox- 34 Although in vitro studies suggested that HCQ is more effective and less toxic than CQ, 35, 36 no evidence of antiviral activity or clinical benefit was found for HCQ-azithromycin combination therapy in patients with severe cases of COVID-19. 37 The CQ/HCQ cardiac safety profile is being questioned due to their known cardiotoxic effects, including vasodilatation, hypotension, hypokalemia, negative inotropy, and arrhythmias. Using the QT interval as the marker for electrocardiographic safety, a small increase in QT associated with the use of chloroquine (not hydroxychloroquine) was observed in subjects free of COVID-19, and no increased mortality associated with the use of hydroxychloroquine. 39 In an observational study, the association between hydroxychloroquine use and intubation or death at a large medical center in New York city was examined. In case, HCQ administration was not associated with either a significantly lowered or an increased risk of the composite endpoint of intubation or death. 40 Even so, care and careful monitoring for cardiac arrhythmias are essential while using these drugs alone or in combination with azithromycin, especially in patients with comorbidities as cirrhosis, heart failure, or preexisting QT-prolongation. 41 Randomized, controlled trials of hydroxychloroquine in patients with COVID-19 are needed. Studies of the antiparasitic agents nitazoxanide and ivermectin have reported broad-spectrum antiviral activity in vitro. Therefore, these drugs are being investigated in randomized controlled clinical trials for the management of acute respiratory infections, including Nitazoxanide is an active metabolite that has demonstrated potent activity against SARS-CoV-2 in vitro, yielding inhibitory concentrations in the micromolar range for infected Vero E6 cells. 26 It is believed that this activity is due to interference with pathways in the host involved in viral replication, rather than virus-specific pathways, where innate antiviral mechanisms are upregulated by amplification of cytoplasmic RNA sensing and type I IFN pathways. 42, 43 Ivermectin was found to inhibit SARS-CoV-2 in an in vitro study Teicoplanin, an antibiotic used to treat staphylococcal infections, has been shown to inhibit the first stage of the MERS-CoV life cycle in human cells. This activity appears to be conserved against SARS-CoV-2 in vitro. 45 Baricitinib, a selective JAK1 and JAK2 inhibitor, has been identified as a potential treatment for SARS-CoV-2 that targets host pathways. Stebbing et al 46 In general, the pharmacological treatment in nonhospital settings is not recommended, as well as for young, healthy patients with mild symptoms, and without comorbidities. 50 Through the clinical treatment of the COVID-19, it has been found that neuraminidase inhibitors (such as oseltamivir, peramivir, and zanamivir) are not sufficient, as this viral enzyme is not produced by coronaviruses. Drugs such as ganciclovir, acyclovir, and ribavirin and lopinavir/ritonavir are have also been shown to be ineffective for serious cases and are thus not recommended for clinical application in these patients. 28 Although SARS-CoV-2 infection is associated with a cytokine storm triggered by overactivation of the immune system, the corticosteroids treatment was not initially recommended for viral pneumo-nia, only for patients with refractory shock or acute respiratory distress syndrome. 18, [49] [50] [51] Currently, a systematic living review and network meta-analysis with data from eight randomized trials (7184 participants) made a strong recommendation for use of corticosteroids in severe and critical COVID-19 because there is a lower risk of death among people treated with systemic corticosteroids (moderate certainty evidence). On the other hand, it suggests not to use corticosteroids in the treatment of patients with nonsevere COVID-19 (weak or conditional recommendation based on insufficient certainty evidence), but should not be stopped for those who are already treated with systemic corticosteroids for other reasons as chronic autoimmune diseases. 52 In addition, the management of patients with COVID-19 showed that an artificial liver blood purification system could quickly clear inflammation mediators to suppress cytokine storm, but the repair system may be delayed for excessive clarity. 53 It has been reported that remdesivir with chloroquine or IFN-β can inhibit SARS-CoV-2 replication in vivo and in vitro, which is better than that of lopinavir/ritonavir-IFN-β against MERS-CoV. However, its effectiveness and safety still need to be verified in clinical trials. 54 Finally, it should be noted that therapeutic-intensity anticoagulation is not rec- The authors declare no conflict of interest. Discovering drugs to treat coronavirus disease 2019 (COVID-19) COVID-19: what is next for public health? Q&A: the novel coronavirus outbreak causing COVID-19 Should patients stop their biologic treatment during the COVID-19 pandemic A novel coronavirus from patients with pneumonia in China Fighting COVID-19 Emerging coronaviruses: genome structure, replication, and pathogenesis Perspectives of immune therapy in coronavirus disease 2019 Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach Griffithsin: an antiviral lectin with outstanding therapeutic potential Therapeutic options for the 2019 novel coronavirus (2019-nCoV) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Homology modeling of TMPRSS2 yields candidate drugs that may inhibit entry of SARS-CoV-2 into human cells Coronavirus membrane fusion mechanism offers as a potential target for antiviral development Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cellcell fusion assay A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 Pathological findings of COVID-19 associated with acute respiratory distress syndrome Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Clinical characteristics of coronavirus disease 2019 in China Potential antiviral therapeutics for 2019 Novel Coronavirus Remdesivir as a possible therapeutic option for the COVID-19 Experimental treatment with favipiravir for COVID-19: an open-label control study COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism COVID-19) Update: Daily Roundup COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression Clinical trials on drug repositioning for COVID-19 treatment Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) Zhejiang Da Xue Xue Bao Yi Xue Ban Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population Observational study of hydroxychloroquine in hospitalized patients with COVID-19 Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets Antiviral treatment of COVID-19 Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro Teicoplanin: an alternative drug for the treatment of COVID-19? COVID-19: combining antiviral and anti-inflammatory treatments Baricitinib for COVID-19: a suitable treatment Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 COVID-19: an overview of the current pharmacological interventions, vaccines, and clinical trials COVID-19 and drug therapy, what we learned Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury A living WHO guideline on drugs for COVID-19 etManagement of corona virus disease-19 (COVID-19): the Zhejiang experience. al. Zhejiang Da Xue Xue Bao Yi Xue Ban Cytokine storm induced by SARS-CoV-2 SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies